Abstract：
Antibody-drug conjugates (ADCs) represent a crucial component of targeted therapies in gastric cancer, potentially altering traditional treatment paradigms. Many ADCs have entered rigorous clinical trials based on biological theories and preclinical experiments. Modality trials have also been conducted in combination with monoclonal antibody therapies, chemotherapies, immunotherapies, and other treatments to enhance the efficacy of drug coordination effects. However, ADCs exhibit limitations in treating gastric cancer, including resistance triggered by their structure or other factors. Ongoing intensive researches and preclinical experiments are yielding improvements, while enhancements in drug development processes and concomitant diagnostics during the therapeutic period actively boost ADC efficacy. The optimal treatment strategy for gastric cancer patients is continually evolving. This review summarizes the clinical progress of ADCs in treating gastric cancer, analyzes the mechanisms of ADC combination therapies, discusses resistance patterns, and offers a promising outlook for future applications in ADC drug development and companion diagnostics.
摘要：
抗体-药物偶联物（ADC）是胃癌靶向治疗的重要组成部分，可能改变传统的治疗模式。许多ADC已经进入基于生物学理论和临床前实验的严格临床试验。还与单克隆抗体疗法结合进行了模态试验，化疗,免疫疗法，和其他治疗方法的疗效增强药物的协调作用。然而,ADC在治疗胃癌方面表现出局限性，包括由其结构或其他因素引发的阻力。正在进行的深入研究和临床前实验正在产生改进，虽然在治疗期间药物开发过程和伴随诊断的增强积极地提高ADC功效。胃癌患者的最佳治疗策略正在不断发展。本文就ADCs治疗胃癌的临床进展作一综述,分析ADC联合治疗的机制，讨论阻力模式，并为ADC药物开发和伴随诊断的未来应用提供了有希望的前景。
